Brought to you by 
Hemispherx Biopharma nets $14.2mm with private sale of shares
16 Jun 2009
Executive Summary
Hemispherx Biopharma (developing infectious disease, cancer, and immunology drug candidates) has netted $14.2mm through the sale of 13.6mm shares at $1.10 each (a 53% premium) to two institutional investors. The backers also received Series A warrants to buy another 6.1mm common shares; the Series I five-year warrants enable the holder to purchase shares for $1.65 each and the Series II warrants are exercisable for 3mm shares within 45 days at $1.10. Rodman & Renshaw was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hemispherx Biopharma nets $14.2mm with private sale of shares
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice